Detalhe da pesquisa
1.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591293
2.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Lung Cancer
; 193: 107821, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38820979
3.
Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA.
Eur Respir J
; 52(1)2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794129
4.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol
; 18(6): 755-768, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001859
5.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med
; 28(11): 2374-2380, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36008722